eMedicine Specialties > Pediatrics: Surgery > Urology

Posterior Urethral Valves: Differential Diagnoses & Workup

Author: Martin David Bomalaski, MD, FAAP, Pediatric Urologist, Alaska Southcentral Urology Specialists
Contributor Information and Disclosures

Updated: Jun 12, 2008

Differential Diagnoses

Antenatal Hydronephrosis
Urinary Tract Infection

Other Problems to Be Considered

Anterior urethral valves
Urethral stricture disease
Detrusor sphincter dyssynergy
Diurnal urinary incontinence
Pediatric renal insufficiency

Workup

Laboratory Studies

  • Immediately following birth, the infant's serum chemistries are the same as the mother's. Therefore, serum values for creatinine and BUN should be obtained at least 24 hours after birth. In utero, the placenta functions as the major blood filter for the fetus, with waste passed on to the mother. Observing serum chemistries for several days to weeks is important to determine the true status of the newborn's renal function.
  • The normal newborn kidney is still undergoing maturation at birth, and infant glomerular filtration rate (GFR) continues to improve during the first several months of life. Because of renal immaturity at birth, the newborn is unable to concentrate urine and is susceptible to dehydration. This defect is exacerbated by renal dysplasia such as that found with posterior urethral valves (PUVs).
  • As renal maturation continues, the serum creatinine clearance normally improves. If significant renal dysplasia or damage has occurred, the serum creatinine fails to reach a normal level during the first year of life. Serum creatinine levels greater than 0.8 mg/dL during the first year of life have been demonstrated to be associated with poor long-term renal function.

Imaging Studies

  • Renal and bladder ultrasonography
    • Every child with antenatal hydronephrosis requires renal and bladder ultrasonography assessment in the immediate postnatal period. Focus should be directed towards appearance of the renal parenchyma, evidence of renal collecting system dilatation, bladder wall thickness, and presence of ascites.
    • Because newborns commonly have relative hypovolemia during the first few days of life, perform repeat ultrasonography after the first week of life if previous findings were normal in a child with previously diagnosed antenatal hydronephrosis before making a final determination that the hydronephrosis has resolved (see History).
  • Voiding cystourethrography
    • The key to the workup of any child with antenatal hydronephrosis is voiding cystourethrography (VCUG). Perform VCUG during voiding and under fluoroscopy, with imaging of the posterior urethra.
    • The diagnosis of PUV is indicated by visualization of the valve leaflets. Other clues to the diagnosis are a thickened trabeculated bladder, a dilated or elongated posterior urethra, and a hypertrophied bladder neck (see Media files 1-2). Diverticula, cellules, vesicoureteral reflux, and reflux into the ejaculatory ducts secondary to elevated bladder and urethral pressures may also be present (see Media file 2).
  • Renal scintigraphy
    • Although not necessary in every child, renal scintigraphy may be helpful in some cases. It should not be performed in the neonatal period because renal immaturity does not allow for accurate estimation of renal function. If renal dysplasia is suspected, nuclear imaging can determine relative renal function. Some children may have secondary ureterovesical junction obstruction due to bladder hypertrophy.
    • Tc-dimercaptosuccinic acid (DMSA), glucoheptonate, and mercaptoacetyl triglycine (MAG-3) renal scintigraphy are cortical imaging studies that provide information about relative renal function (each kidney relative to the other) and intrarenal function (eg, photopenic areas within the kidney indicate scarring or dysplasia). Additionally, the MAG-3 renal scan with furosemide (Lasix) provides information about renal drainage and possible obstruction.

Other Tests

  • Urodynamic evaluation provides information about bladder storage and emptying. The mature bladder should store urine at a low pressure and then completely empty at appropriate pressures.
  • The term "valve bladder" is used to describe patients with PUV and a fibrotic noncompliant bladder. These patients are at risk of developing hydroureteronephrosis, progressive renal deterioration, recurrent infections, and urinary incontinence.
  • Patients with PUV require periodic urodynamic testing throughout childhood because bladder compliance may further deteriorate over time.

Procedures

  • Cystoscopy serves both diagnostic and therapeutic functions in these infants. Appropriately-sized cystoscopes (<8F) are needed to avoid injury to the urethra.
    • Diagnostic cystoscopy: Confirmation with cystoscopy is required in every child in whom PUV is suggested after VCUG. In some, the filling defect observed on VCUG may represent only external sphincter contraction during voiding. In others, the valve leaflets are confirmed.
    • Therapeutic cystoscopy (ie, transurethral incision of the PUVs): Multiple techniques have been described for ablating the valves. Disruption of the obstructing membrane by blind passage of a valve hook is now only of historic interest. Currently, valves are disrupted under direct vision by cystoscopy using an endoscopic loop, Bugbee electrocauterization, or laser fulguration. The objective is to relieve the obstruction by cutting the valves at the 12-, 5-, and 7-o'clock positions. Perform this in the least traumatic fashion to avoid secondary urethral stricture or injury to the urethral sphincter mechanism.
  • In some patients, the urethra may be too small for the available cystoscopic instrumentation. Fortunately, because of continued advancements in pediatric endoscopic equipment, this is an uncommon occurrence. When this situation arises, a temporary vesicostomy is performed.

More on Posterior Urethral Valves

Overview: Posterior Urethral Valves
Differential Diagnoses & Workup: Posterior Urethral Valves
Treatment & Medication: Posterior Urethral Valves
Follow-up: Posterior Urethral Valves
Multimedia: Posterior Urethral Valves
References

References

  1. Young HH, Fronz WA, Baldwin JC. Congenital obstruction of the posterior urthera. J Urol. 1919;3:289.

  2. Dewan PA, Goh DG. Variable expression of the congenital obstructive posterior urethral membrane. Urology. Mar 1995;45(3):507-9. [Medline].

  3. Thomas DF, Gordon AC. Management of prenatally diagnosed uropathies. Arch Dis Child. Jan 1989;64(1 Spec No):58-63. [Medline].

  4. Dinneen MD, Dhillon HK, Ward HC, Duffy PG, Ransley PG. Antenatal diagnosis of posterior urethral valves. Br J Urol. Sep 1993;72(3):364-9. [Medline].

  5. Bomalaski MD, Anema JG, Coplen DE, Koo HP, Rozanski T, Bloom DA. Delayed presentation of posterior urethral valves: a not so benign condition. J Urol. Dec 1999;162(6):2130-2. [Medline].

  6. Bani Hani O, Prelog K, Smith GH. A method to assess posterior urethral valve ablation. J Urol. Jul 2006;176(1):303-5. [Medline].

  7. Narasimhan KL, Mahajan JK, Kaur B, Mittal BR, Bhattacharya A. The vesicoureteral reflux dysplasia syndrome in patients with posterior urethral valves. J Urol. Oct 2005;174(4 Pt 1):1433-5; discussion 1435. [Medline].

  8. Atwell JD. Posterior urethral valves in the British Isles: a multicenter B.A.P.S. review. J Pediatr Surg. Feb 1983;18(1):70-4. [Medline].

  9. DeFoor W, Tackett L, Minevich E, McEnery P, Kitchens D, Reeves D, et al. Successful renal transplantation in children with posterior urethral valves. J Urol. Dec 2003;170(6 Pt 1):2402-4. [Medline].

  10. Gonzales ET. Posterior urethral valves and other urethral anomalies. In: Walsh PC, et al, eds. Campbell's Urology. 7th ed. Philadelphia, Pa: W.B. Saunders; 1996:2069-91.

  11. Koo HP, Bunchman TE, Flynn JT, Punch JD, Schwartz AC, Bloom DA. Renal transplantation in children with severe lower urinary tract dysfunction. J Urol. Jan 1999;161(1):240-5. [Medline].

  12. Krishnan A, de Souza A, Konijeti R, Baskin LS. The anatomy and embryology of posterior urethral valves. J Urol. Apr 2006;175(4):1214-20. [Medline].

  13. Parkhouse HF, Barratt TM, Dillon MJ, Duffy PG, Fay J, Ransley PG, et al. Long-term outcome of boys with posterior urethral valves. Br J Urol. Jul 1988;62(1):59-62. [Medline].

  14. Reinberg Y, de Castano I, Gonzalez R. Prognosis for patients with prenatally diagnosed posterior urethral valves. J Urol. Jul 1992;148(1):125-6. [Medline].

  15. Salam MA. Posterior urethral valve: Outcome of antenatal intervention. Int J Urol. Oct 2006;13(10):1317-22. [Medline].

  16. Smith GH, Canning DA, Schulman SL, Snyder HM 3rd, Duckett JW. The long-term outcome of posterior urethral valves treated with primary valve ablation and observation. J Urol. May 1996;155(5):1730-4. [Medline].

  17. Tejani A, Butt K, Glassberg K, Price A, Gurumurthy K. Predictors of eventual end stage renal disease in children with posterior urethral valves. J Urol. Oct 1986;136(4):857-60. [Medline].

Further Reading

Keywords

posterior urethral valves, PUVs, congenital obstructing membranes, Amussat valvula, Amussat's valvula, congenital obstructing posterior urethral membrane, COPUM, urinary tract obstruction, renal transplant, renal insufficiency, end-stage renal disease, ESRD, thickened bladder, antenatal hydronephrosis, urinary tract infection, UTI, voiding dysfunction, diurnal enuresis, proteinuria, pulmonary distress, oligohydramnios

Contributor Information and Disclosures

Author

Martin David Bomalaski, MD, FAAP, Pediatric Urologist, Alaska Southcentral Urology Specialists
Martin David Bomalaski, MD, FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, and American Urological Association
Disclosure: Nothing to disclose.

Medical Editor

Bartley G Cilento, Jr, MD, Instructor, Department of Surgery, Division of Urology, Children's Hospital of Boston and Harvard Medical School
Bartley G Cilento, Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Urological Association, and Massachusetts Medical Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc
Disclosure: Pfizer Inc Stock Investment from broker recommendation; Avanir Pharma Stock Investment from broker recommendation

Managing Editor

Harry P Koo, MD, Chairman of Urology Division and Director of Pediatric Urology, Virginia Commonwealth University; Professor of Surgery, VCU School of Medicine, Medical College of Virginia; Director of Urology, Children's Hospital of Richmond
Harry P Koo, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Surgeons, and American Urological Association
Disclosure: Nothing to disclose.

CME Editor

Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine
Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine
Disclosure: Baxter Honoraria Consulting; Pfizer Honoraria Consulting

Chief Editor

Marc Cendron, MD, Associate Professor of Surgery, Harvard School of Medicine; Consulting Staff, Department of Urological Surgery, Children's Hospital Boston
Marc Cendron, MD is a member of the following medical societies: American Academy of Pediatrics, American Urological Association, European Society for Paediatric Urology, Johns Hopkins Medical and Surgical Association, New Hampshire Medical Society, Society for Fetal Urology, and Society for Pediatric Urology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.